Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance

With an estimated 1.5 billion people affected worldwide and MASLD now impacting 38% of the global population, clinicians need scalable, noninvasive tools that use routine laboratory data to identify high-risk patients sooner and standardize referrals. A new system has launched to address this need by combining certified algorithms with biomarker-based diagnostics across the liver care pathway.

Roche (Basel, Switzerland) has launched the Liver Disease Panel, a comprehensive library of certified healthcare algorithms designed to support chronic liver disease management from early risk identification to cancer surveillance. Available on the navify Algorithm Suite, the panel integrates with existing hospital systems to provide a single point of access for ordering and reviewing algorithm outputs. The solution is being rolled out in markets across Europe.

The panel combines biomarker-based diagnostics with advanced digital algorithms to enable noninvasive assessment using routinely available clinical data. A key component is LiverPRO, a CE‑marked algorithm developed with the health tech company Evido. LiverPRO adapts to existing patient data, requiring age and a minimum of three out of nine common blood-based biomarkers to assess the risk of liver fibrosis, enabling timely identification and standardized referrals.

Additional tools in the library include ADAPT used with Elecsys PRO‑C3 to assess fibrosis severity and GAAD used with Elecsys AFP and Elecsys PIVKA II to aid in the diagnosis of hepatocellular carcinoma. The platform also consolidates widely used clinical scores, including FIB‑4, MELD, ALBI, Child‑Pugh, and the Lille Model, into a single secure environment. Each solution is certified and automated within clinical workflows, with patient data handled to the standards required for a medical device.

Roche states that this approach reduces reliance on invasive testing and supports a proactive, preventive model of care. LiverPRO has been endorsed in the EASL Patient Trajectory Guidance as an alternative and scalable first‑line test for liver fibrosis. The navify platform supporting the panel is ISO/IEC 27001 certified, encrypts data at rest and in transit, and is operated in compliance with HIPAA and GDPR.

“Chronic liver disease impacts millions of lives around the world, and patients need effective care at every stage of their journey,” said Matt Sause, CEO Roche Diagnostics. “With the Liver Disease Panel, we are enabling clinicians to identify risk earlier, intervene sooner, and manage this disease more effectively, helping to improve liver care and support better patient health.”